AR031073A1 - A NEW CRYSTALLINE SHAPE OF 6-HYDROXI-3- (4- [2- (PIPERIDIN-1-IL) ETOXI) PHENOXI CHLORIDE HYDROXYIDE BENZO (B) THIOPHEN; PHARMACEUTICAL FORMULATIONS THAT INCLUDE SUCH CRYSTAL FORM; PROCEDURE TO PREPARE THE MENTIONED CRYSTAL FORM AND THE CRYSTAL FORM THAT IS OBTAINED WITH THE PRO - Google Patents
A NEW CRYSTALLINE SHAPE OF 6-HYDROXI-3- (4- [2- (PIPERIDIN-1-IL) ETOXI) PHENOXI CHLORIDE HYDROXYIDE BENZO (B) THIOPHEN; PHARMACEUTICAL FORMULATIONS THAT INCLUDE SUCH CRYSTAL FORM; PROCEDURE TO PREPARE THE MENTIONED CRYSTAL FORM AND THE CRYSTAL FORM THAT IS OBTAINED WITH THE PROInfo
- Publication number
- AR031073A1 AR031073A1 ARP000103928A ARP000103928A AR031073A1 AR 031073 A1 AR031073 A1 AR 031073A1 AR P000103928 A ARP000103928 A AR P000103928A AR P000103928 A ARP000103928 A AR P000103928A AR 031073 A1 AR031073 A1 AR 031073A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystal form
- piperidin
- benzo
- cancer
- phenoxi
- Prior art date
Links
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 title 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940011871 estrogen Drugs 0.000 abstract 2
- 239000000262 estrogen Substances 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 206010067269 Uterine fibrosis Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000001514 prostate carcinoma Diseases 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 230000003827 upregulation Effects 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se refiere a un nuevo hidrato cristalino del clorhidrato de 6- hidroxi-3-(4-[2-(piperidin-1-il)etoxil]-fenoxi]-2-(4-metoxifenil)benzo[b]tiofeno que posee el siguiente diagrama de difraccion en Rx. que comprende los siguientes picos: 7,9 +- 0,2, 10,7 +- 0,2, 14,9 +- 0,2, 15,9 +- 0,2, 18,3 +- 0,2, y 20,6 +- 0,2s en 2c; cuando se obtiene a partir de una fuente de radiacion de cobre. La invencion comprende el uso de dicho compuesto, incluyendo la inhibicion de estados de enfermedad asociados con la privacion de estrogenos que incluyen enfermedades cardiovasculares, hiperlipidemia y osteoporosis; y la inhibicion de otros trastornos patologicos tales como la endometriosis, la fibrosis uterina, el cáncer dependiente de estrogenos (incluyendo el cáncer de mama y uterino), el cáncer de prostata, la hiperplasia prostática benigna, trastornos del SNC que incluyen la enfermedad de Alzheimer, prevencion del cáncer mama y regulacion positiva de la ChAT. También se describen y reivindican los objetos restantes mencionados en el título.The present invention relates to a novel crystalline hydrate of 6- hydroxy-3- (4- [2- (piperidin-1-yl) ethoxy] -phenoxy] -2- (4-methoxyphenyl) benzo [b] thiophene hydrochloride which has the following diffraction diagram in Rx. comprising the following peaks: 7.9 + - 0.2, 10.7 + - 0.2, 14.9 + - 0.2, 15.9 + - 0, 2, 18.3 + - 0.2, and 20.6 + - 0.2s in 2c; when obtained from a source of copper radiation The invention comprises the use of said compound, including the inhibition of states of disease associated with estrogen deprivation that include cardiovascular disease, hyperlipidemia and osteoporosis; and the inhibition of other pathological disorders such as endometriosis, uterine fibrosis, estrogen-dependent cancer (including breast and uterine cancer), cancer of prostate, benign prostatic hyperplasia, CNS disorders that include Alzheimer's disease, prevention of breast cancer and positive regulation of ChAT. in and claim the remaining objects mentioned in the title.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14628699P | 1999-07-29 | 1999-07-29 | |
| US14757099P | 1999-08-06 | 1999-08-06 | |
| US14977399P | 1999-08-19 | 1999-08-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031073A1 true AR031073A1 (en) | 2003-09-10 |
Family
ID=27386379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000103928A AR031073A1 (en) | 1999-07-29 | 2000-07-28 | A NEW CRYSTALLINE SHAPE OF 6-HYDROXI-3- (4- [2- (PIPERIDIN-1-IL) ETOXI) PHENOXI CHLORIDE HYDROXYIDE BENZO (B) THIOPHEN; PHARMACEUTICAL FORMULATIONS THAT INCLUDE SUCH CRYSTAL FORM; PROCEDURE TO PREPARE THE MENTIONED CRYSTAL FORM AND THE CRYSTAL FORM THAT IS OBTAINED WITH THE PRO |
Country Status (44)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6335500A (en) * | 1999-07-29 | 2001-02-19 | Eli Lilly And Company | A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride |
| CA2408563A1 (en) * | 2000-05-08 | 2001-11-15 | Eli Lilly And Company | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof |
| EP1757291A3 (en) * | 2000-05-08 | 2009-07-15 | Eli Lilly & Company | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof |
| US7122203B2 (en) | 2000-05-08 | 2006-10-17 | Eli Lilly And Company | Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof |
| EP1157996A1 (en) * | 2000-05-23 | 2001-11-28 | JENAPHARM GmbH | New solid forms of mesoprogestin 11beta-(4E-(hydroxyiminomethyl)-phenyl)-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on |
| CA2426007A1 (en) * | 2000-10-20 | 2002-05-02 | Eli Lilly And Company | A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| AU2002230409A1 (en) | 2000-11-27 | 2002-06-03 | Eli Lilly And Company | Process for preparing 3-aryl-benzo(b)thiophenes |
| CA2393720C (en) * | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| PT1773811E (en) * | 2004-07-22 | 2010-10-19 | Lilly Co Eli | A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510357A (en) | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
| JP3989569B2 (en) * | 1995-02-28 | 2007-10-10 | イーライ リリー アンド カンパニー | Benzothiophene compounds, intermediates, compositions and methods |
| ZA9710262B (en) * | 1996-11-19 | 1999-05-13 | Lilly Co Eli | Process for the synthesis of benzothiophenes |
| ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
-
2000
- 2000-07-17 WO PCT/US2000/016333 patent/WO2001009116A2/en not_active Ceased
- 2000-07-17 EP EP00950223A patent/EP1204656A2/en not_active Ceased
- 2000-07-17 AU AU63356/00A patent/AU6335600A/en not_active Abandoned
- 2000-07-18 LV LVP-00-94A patent/LV12623B/en unknown
- 2000-07-21 RO ROA200000736A patent/RO121851B1/en unknown
- 2000-07-24 CZ CZ20002716A patent/CZ299311B6/en not_active IP Right Cessation
- 2000-07-24 ID IDP20000629D patent/ID27078A/en unknown
- 2000-07-25 HR HR20000503A patent/HRP20000503B1/en not_active IP Right Cessation
- 2000-07-27 NL NL1015821A patent/NL1015821C2/en not_active IP Right Cessation
- 2000-07-27 IL IL13755300A patent/IL137553A/en not_active IP Right Cessation
- 2000-07-27 CO CO00056521A patent/CO5180570A1/en active IP Right Grant
- 2000-07-27 TR TR2000/02206A patent/TR200002206A2/en unknown
- 2000-07-28 KR KR1020000043651A patent/KR100697177B1/en not_active Expired - Fee Related
- 2000-07-28 SI SI200000172A patent/SI20426A/en not_active IP Right Cessation
- 2000-07-28 FI FI20001722A patent/FI20001722A7/en unknown
- 2000-07-28 MY MYPI20003453A patent/MY128764A/en unknown
- 2000-07-28 LT LT2000076A patent/LT4790B/en not_active IP Right Cessation
- 2000-07-28 NO NO20003879A patent/NO20003879L/en not_active Application Discontinuation
- 2000-07-28 AR ARP000103928A patent/AR031073A1/en unknown
- 2000-07-28 BR BR0003209-3A patent/BR0003209A/en not_active Application Discontinuation
- 2000-07-28 AT AT0132400A patent/AT502318A1/en not_active Application Discontinuation
- 2000-07-28 TW TW089115154A patent/TWI276437B/en not_active IP Right Cessation
- 2000-07-28 GB GB0018641A patent/GB2352717A/en not_active Withdrawn
- 2000-07-28 SG SG200004288A patent/SG91296A1/en unknown
- 2000-07-28 IT IT2000MI001759A patent/IT1318660B1/en active
- 2000-07-28 MX MXPA00007461A patent/MXPA00007461A/en active IP Right Grant
- 2000-07-28 UA UA2000074563A patent/UA72885C2/en unknown
- 2000-07-28 BE BE2000/0478A patent/BE1013411A3/en not_active IP Right Cessation
- 2000-07-28 FR FR0009969A patent/FR2796944B1/en not_active Expired - Fee Related
- 2000-07-28 SV SV2000000132A patent/SV2002000132A/en unknown
- 2000-07-28 GR GR20000100265A patent/GR1004084B/en unknown
- 2000-07-28 PT PT102502A patent/PT102502A/en not_active IP Right Cessation
- 2000-07-28 PL PL00341749A patent/PL341749A1/en not_active Application Discontinuation
- 2000-07-28 HU HU0003001A patent/HUP0003001A2/en unknown
- 2000-07-28 JP JP2000228939A patent/JP2001064277A/en active Pending
- 2000-07-28 SE SE0002792A patent/SE0002792L/en unknown
- 2000-07-28 MD MDA20000162A patent/MD2336G2/en not_active IP Right Cessation
- 2000-07-28 CN CNB001222376A patent/CN1138770C/en not_active Expired - Fee Related
- 2000-07-28 LU LU90617A patent/LU90617B1/en active
- 2000-07-28 DK DK200001151A patent/DK200001151A/en not_active Application Discontinuation
- 2000-07-28 CA CA002314682A patent/CA2314682A1/en not_active Abandoned
- 2000-07-28 DE DE10036854A patent/DE10036854A1/en not_active Withdrawn
- 2000-07-29 DZ DZ000126A patent/DZ3060A1/en active
- 2000-07-31 PE PE2000000757A patent/PE20010385A1/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031073A1 (en) | A NEW CRYSTALLINE SHAPE OF 6-HYDROXI-3- (4- [2- (PIPERIDIN-1-IL) ETOXI) PHENOXI CHLORIDE HYDROXYIDE BENZO (B) THIOPHEN; PHARMACEUTICAL FORMULATIONS THAT INCLUDE SUCH CRYSTAL FORM; PROCEDURE TO PREPARE THE MENTIONED CRYSTAL FORM AND THE CRYSTAL FORM THAT IS OBTAINED WITH THE PRO | |
| AR029176A1 (en) | A NEW CRYSTAL FORM OF 6-HYDROXI-3- (4- [2- (PIPERIDIN-1-IL) ETOXI] PHENOXI) CHLORIDE HYDROXY BENZO [B] THIOPHEN APPLICABLE IN THE INHIBITION, BETWEEN OTHERS , OF PATHOLOGICAL STATES ASSOCIATED WITH THE REDUCTION OF THE PLASMATIC LEVELS OF STROGENS AND PHARMACEUTICAL COMPOSITION THAT COMP | |
| DE602004006994D1 (en) | 3-aryloxy und 3-heteroaryloxy substituierte benzo(b) thiophene als therapeutische wirkstoffe mit pi3k aktivität | |
| IL158899A0 (en) | Pharmaceutical compositions for inhibiting angiogenesis containing oleuropein and derivatives thereof | |
| AR010538A1 (en) | PHARMACEUTICAL COMPOSITION TO INHIBIT THE DEVELOPMENT OF BREAST CANCER IN MENOPAUSIC WOMEN INCLUDING RALOXIFENO (6- [HIDROXI] -2- (4-HIDROXIFENIL) -BENZO (B) -TIEN-3-IL] -4 - [- 2- ( 1-PIPERIDINYL) ETOXI-PHENYL]] - METHANONE | |
| WO2002034741A3 (en) | A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE | |
| BR0213652A (en) | Continuous Centrifuge and Centrifuge Basket | |
| US5571808A (en) | Method for treating smoking-related bone loss | |
| RU2000120574A (en) | NEW CRYSTALLINE FORM 6-HYDROXY-3- (4- [2- (PIPERIDIN-1-IL) ETOXI] PHENOXY) -2- (4-METHOFYNYL) BENZ [b] TIOPHENE HYDROCHLORIDE | |
| RU2000120575A (en) | NEW CRYSTALLINE FORM of 6-HYDROXY-3- (4- [2- (PIPERIDIN-1-IL) ETOXY] PHENOXY) -2- (4-METHOXYPHENYL) BENZE [b] THIOPHENE HYDROCHLORIDE | |
| CN109237242A (en) | A kind of environmental improvement equipment mounting bracket | |
| ECSP003592A (en) | A NEW CRYSTALINE SHAPE OF 6- HYDROXY- 3- (4- [2- (PIPERIDIN-1-IL) ETOXI] PHENOXI) -2- (4-METOXYPHENYL) BENZO [b] THIOPHEN | |
| DK1150683T3 (en) | Use of dienogest in higher dosage | |
| ECSP003593A (en) | A NEW CRYSTALINE SHAPE OF 6- HYDROXY- 3- (4- [2- (PIPERIDIN-1-IL) ETOXI] PHENOXI) -2- (4-METOXYPHENYL) BENZO [b] THIOPHEN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |